CD163 and colorectal cancer: Moreover, previous studies reported that immune cell spatial heterogeneity may be associated with cancer development and response to immunotherapy.50–52 Consistent with these findings, our spatial analysis revealed that an increased density of PD-1+ cells and CD68+ CD163+ macrophages was localized close to colorectal cancer (<30 μm) in mCRC patients who achieved a clinical response from sintilimab plus anlotinib.